Clinical Trial Update: A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy [Phase 3]

View source ↗

Summary

Phase 3 randomized trial comparing SKB264 against investigator's choice chemotherapy in patients with unresectable locally advanced, relapsed, or metastatic HR+…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Investigator's Choice Chemotherapy
• SKB264

Snippet

Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Conditions: Metastatic Breast Cancer | Phase 3 | Status: RECRUITING